uniQure NV (NASDAQ:QURE)’s share price dropped 1.9% during mid-day trading on Thursday . The stock traded as low as $7.52 and last traded at $7.57, with a volume of 113,287 shares changing hands. The stock had previously closed at $7.72.

QURE has been the subject of several recent research reports. Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a research note on Thursday, June 2nd. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of uniQure NV in a research note on Thursday, March 24th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $26.00 price objective on shares of uniQure NV in a research note on Tuesday, April 5th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Finally, Leerink Swann restated a “buy” rating on shares of uniQure NV in a research note on Sunday, June 12th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. uniQure NV presently has a consensus rating of “Buy” and an average price target of $30.80.

The stock’s market cap is $182.42 million. The company has a 50-day moving average of $9.79 and a 200-day moving average of $13.08.

uniQure NV (NASDAQ:QURE) last posted its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. On average, equities research analysts expect that uniQure NV will post ($3.14) EPS for the current year.

An institutional investor recently raised its position in uniQure NV stock. Columbus Circle Investors increased its position in shares of uniQure NV (NASDAQ:QURE) by 493.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,548 shares of the company’s stock after buying an additional 94,422 shares during the period. Columbus Circle Investors owned 0.47% of uniQure NV worth $1,878,000 as of its most recent SEC filing.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.